Zárate A, Basurto L, Saucedo R

Language: Spanish
References: 9
Page: 188-191
PDF size: 59.45 Kb.

ABSTRACT

The osteoporosis is the most common type of bone disease, a systemic illness of multicausal etiopathogenesis. A progressive bone loss and qualitative alterations in the architecture, resulting in a loss of strength of bones to such an extent that trauma will cause fractures. Osteoporosis occurs when the body fails to form enough new bone or when to much is reabsorbed. There are no symptoms in the early stages of the disease. Bone mineral density estimated by densitometry or DXA scan is the method of diagnosis. The treatment of osteoporosis is based on various agents, such as bisphosphonates, selective estrogen receptor modulators, parathyroid hormone, estrogens. Effective treatment options exist to reduce the risk for fractures taking into account risk assessment. To monitor bone loss BMD testing is performed between one and two years at DXA centers of accepted quality assurance measures. Patients receiving pharmacologic intervention should have BMD testing 2 years after starting therapy and every 2 years thereafter.

REFERENCES

1. Qaseem A, Shekelle P, Hopkins R, Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. 2008; 149: 404-415.

2. Canalis E, Guistina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905-916.

3. Zárate A, Saucedo R, Basurto L. Recomendaciones para el manejo de la osteoporosis. Gaceta Med Mex 2004; 140: 263-268.

4. Stevensson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005; 51: 113-126.

5. Simon JA. Does osteopenia warrant treatment? Menopause 2005; 12: 639-648.

6. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006; 13: 340-367.

7. Zárate A, Basurto L, Hernández M, Saucedo R. La terapéutica actual de la osteoporosis en la mujer y en el hombre. Conducta terapéutica para la osteoporosis. Rev Med Inter 2007; 23: 210-216.

8. Ebeling PR. Osteoporosis in men. N Engl J Med 2008; 358: 1474-1480.

9. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R. Effect of testosterone therapy on lumbar mineral density in elderly men. The Aging Male 2008; 11: 1-6.